Susann Oconnor
Nurse Practitioner · Mobile, ALNPI 1528009784
Payments from drug & device makers
Across 320 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$774
- Amarin Pharma, Inc.$379
- Lilly USA, LLC$344
- Bayer$291
- Amgen$253
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,776100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $1,095 |
| AstraZeneca | 23 | $774 |
| Amarin Pharma, Inc. | 52 | $379 |
| Lilly USA, LLC | 22 | $344 |
| Bayer | 16 | $291 |
| Amgen | 16 | $253 |
| Novartis | 22 | $246 |
| Boehringer Ingelheim | 14 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $196 |
| Kowa Pharmaceuticals America, Inc. | 20 | $155 |
| Regeneron Healthcare Solutions, Inc. | 6 | $132 |
| Xeris Pharmaceuticals, Inc. | 6 | $113 |
| Dexcom, Inc. | 7 | $101 |
| Esperion Therapeutics, Inc. | 6 | $96 |
| Corcept Therapeutics | 4 | $75 |
| BD | 2 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $35 |
| Chiesi USA, Inc. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Pfizer | 1 | $17 |
| Medtronic | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$375
How this compares
$4,794 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 378 | $564,997 |
| JardianceEmpagliflozin | 167 | $192,107 |
| Repatha SureclickEvolocumab | 128 | $167,283 |
| FarxigaDapagliflozin Propanediol | 150 | $145,667 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $140,477 |
| MounjaroTirzepatide | 86 | $106,916 |
| VascepaIcosapent Ethyl | 130 | $98,893 |
| JanuviaSitagliptin Phosphate | 71 | $84,617 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $65,324 |
| Praluent PenAlirocumab | 46 | $43,462 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $36,198 |
| TrulicityDulaglutide | 21 | $31,688 |
| FiaspInsulin Aspart (Niacinamide) | 18 | $31,203 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $29,876 |
| Humalog Kwikpen U-100Insulin Lispro | 85 | $29,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $1,095 | $624,886433 claims |
| Boehringer IngelheimJardiance, Tradjenta | $214 | $203,177182 claims |
| AstraZenecaFarxiga | $774 | $145,667150 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $344 | $143,174119 claims |
| MerckJanuvia | $20 | $84,61771 claims |
| Esperion Therapeutics, Inc.Nexletol | $96 | $8,04612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Mobile
- Ardie Pack MabienMobile$126K
- Wilma BaliemMobile$13K
- Erin RiscoMobile$11K
- Hope TindleMobile$9K
- Erin TannerAlabaster$141K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.